Differentiating non-epileptic seizures from epileptic seizures in Glut1 deficiency syndrome.


Journal

Developmental medicine and child neurology
ISSN: 1469-8749
Titre abrégé: Dev Med Child Neurol
Pays: England
ID NLM: 0006761

Informations de publication

Date de publication:
24 Apr 2024
Historique:
revised: 13 03 2024
received: 03 09 2023
accepted: 21 03 2024
medline: 24 4 2024
pubmed: 24 4 2024
entrez: 24 4 2024
Statut: aheadofprint

Résumé

To investigate the clinical characteristics of non-epileptic seizures due to transient brain dysfunction caused by energy deficiency after prolonged fasting or exercise in individuals with glucose transporter type 1 deficiency syndrome (Glut1DS), and then elucidate further the seizure features to distinguish non-epileptic seizures from epileptic seizures. This retrospective case-control study included 57 non-epileptic seizures and 23 epileptic seizures (control group) in 14 individuals (11 males, three females; aged 5-44 years, median = 20 years) with Glut1DS, all with a heterozygous pathogenic SLC2A1 mutation. Non-epileptic seizures were classified as paroxysmal altered consciousness (n = 8), movement disorders (n = 35) (eye-head movements, ataxia, spasticity, weakness, involuntary movement), dysaesthesia (n = 8), and vomiting (n = 6) at the peak ages at onset of 5 to 10 years. Ketogenic diet therapy was effective in 33 of 43 (77%) non-epileptic seizures. Providing supplementary food before high-impact exercise or during attacks prevented or mitigated non-epileptic seizures in some individuals. Glut1DS-associated non-epileptic seizures are fundamentally situation-related seizures with specific provoking and ameliorating factors. Non-epileptic seizures can be distinguished from epileptic seizures by the absence of complete consciousness loss and rapid postictal recovery despite prolonged seizures. Non-epileptic seizures are not well recognized but require different therapeutic approaches compared to epileptic seizures. Awareness of the differentiation of non-epileptic seizures from epileptic seizures is essential when performing preventive or therapeutic decision-making for acute exacerbation seizures.

Identifiants

pubmed: 38655597
doi: 10.1111/dmcn.15942
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Research on Rare and Intractable Diseases, Health and Labour Sciences Research.
ID : 20FC1025

Informations de copyright

© 2024 Mac Keith Press.

Références

Papetti L, Parisi P, Leuzzi V, Nardecchia F, Nicita F, Ursitti F, et al. Metabolic epilepsy: an update. Brain Dev 2013; 35: 827–41.
Gras D, Roze E, Caillet S, Méneret A, Doummar D, Billette de Villemeur T, et al. GLUT1 deficiency syndrome: an update. Rev Neurol (Paris) 2014; 170: 91–9.
Klepper J, Akman C, Armeno M, Auvin S, Cervenka M, Cross HJ, et al. Glut1 Deficiency Syndrome (Glut1DS): State of the art in 2020 and recommendations of the international Glut1DS study group. Epilepsia Open 2020; 5: 354–65.
Ito Y, Takahashi S, Kagitani‐Shimono K, Natsume J, Yanagihara K, Fujii T, et al. Nationwide survey of glucose transporter‐1 deficiency syndrome (GLUT‐1DS) in Japan. Brain Dev 2015; 37: 780–9.
Hauser WA, Beghi E. First seizure definitions and worldwide incidence and mortality. Epilepsia 2008; 49 Suppl 1: 8–12.
Klepper J, Leiendecker B, Eltze C, Heussinger N. Paroxysmal nonepileptic events in Glut1 deficiency. Mov Disord Clin Pract 2016; 3: 607–10.
De Vivo DC, Trifiletti RR, Jacobson RI, Ronen GM, Behmand RA, Harik SI. Defective glucose transport across the blood‐brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med 1991; 325: 703–9.
Ichord RN. Perinatal metabolic encephalopathies. In: Swaiman KF, Ashwal S, Ferriero DM, Schor NF, editors. Swaiman's Pediatric Neurology. 5th edition. Principles and Practice. China: Elsevier Saunders, 2012: 100–19.
Pons R, Collins A, Rotstein M, Engelstad K, De Vivo DC. The spectrum of movement disorders in Glut‐1 deficiency. Mov Disord 2010; 25: 275–81.
Anheim M, Maillart E, Vuillaumier‐Barrot S, Flamand‐Rouvière C, Pineau F, Ewenczyk C, et al. Excellent response to acetazolamide in a case of paroxysmal dyskinesias due to GLUT1‐deficiency. J Neurol 2011; 258: 316–7.
Chambon R, Vuillaumier‐Barrot S, Seta N, Wagner S, Sarret C. Partial effectiveness of acetazolamide in a mild form of GLUT1 deficiency: a pediatric observation. Mov Disord 2013; 28: 1749–51.
Michel V, Riant F, Tournier‐Lasserve E, Guehl D, Lagueny A, Bioulac B, et al. Long‐term improvement of paroxysmal dystonic choreathetosis with acetazolamide. J Neurol 2006; 253: 1362–4.
Málaga I, Avila A, Primeaux S, Park JY, Pascual JM. A concise study of acetazolamide in glucose transporter type 1 deficiency (G1D) epilepsy. Epilepsia 2023; 64: e184–9.

Auteurs

Yasushi Ito (Y)

Department of Pediatrics, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Research Department of Pediatric and Maternal Health, Aiiku Research Institute, Maternal & Child Health Center, Imperial Gift Foundation Boshi-Aiiku-Kai, Tokyo, Japan.

Hidetsugu Nakatsukasa (H)

Department of Pediatrics, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.

Yuriko Toyoma (Y)

Department of Pediatrics, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.

Satoru Nagata (S)

Department of Pediatrics, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.

Hirokazu Oguni (H)

Department of Pediatrics, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Epilepsy Center, TMG Asaka Medical Center, Saitama, Japan.

Classifications MeSH